Stem Cell Treatments for Cerebral Palsy are Currently Available at ASCI
Because Cerebral Palsy is a condition that encompasses a group of non-progressive, non-contagious motor conditions that cause physical disability in human development, we aim to treat it with Stem Cell Therapy.
Cerebral refers to the cerebrum, which is the affected area of the brain (although the disorder most likely involves connections between the cortex and other parts of the brain such as the cerebellum), and palsy refers to disorder of movement. Cerebral palsy is caused by damage to the motor control centers of the developing brain and can occur during pregnancy, during childbirth or after birth up to about age three. Resulting limits in movement and posture cause activity limitation and are often accompanied by disturbances of sensation, depth perception and other sight-based perceptual problems, communication ability; impairments can also be found in cognition, and epilepsy is found in about one-third of cases. CP, no matter what the type, is often accompanied by secondary musculoskeletal problems that arise as a result of the underlying etiology.
Asphyxia, Infections, and Inflammation during Intrauterine development seemed to be the causes.
There are 4 types:
- Spastic - 80% and most common; hypertonic and have what is essentially a neuromuscularmobility impairment (rather than hypotonia or paralysis) stemming from an upper motor neuron lesion in the brain as well as the corticospinal tract or the motor cortex. This damage impairs the ability of some nerve receptors in the spine to properly receive gamma amino butyric acid, leading to hypertonia in the muscles signaled by those damaged nerves.
- Ataxic - caused by damage to the cerebellum, and it is common for individuals to have difficulty with visual and/or auditory processing.
- Dyskinetic - is mixed muscle tone – both hypertonia and hypotonia mixed with involuntary motions. People with Dyskinetic CP have trouble holding themselves in an upright, steady position for sitting or walking, and often show involuntary motions.
- Mixed - A combination of the above
Cerebral Palsy Stem Cell Treatment and stem cell therapy. Cerebral Palsy treatment studies and stem cell protocols:
Umbilical cord blood cells for treatment of cerebral palsy; timing and treatment options. Pediatr Res. 2017 Sep 22;: Authors: McDonald CA, Fahey MC, Jenkin G, Miller SL Abstract Cerebral palsy is the most common cause of physical disability in children, and there is no cure. Umbilical cord blood (UCB) cell therapy for the treatment of children with cerebral palsy is currently being assessed in clinical trials. While there is much interest in the use of UCB stem cells for neuroprotection and neuroregeneration, the mechanisms of action are not fully understood. Further, UCB contains many stem and progenitor cells of interest, and we will point out that individual cell types within UCB may elicit specific effects. UCB is a clinically proven source of hemotopoietic stem cells (HSCs). It also contains mesenchymal stromal cells (MSCs), endothelial progenitor cells (EPCs) and immunosupressive cells such as regulatory T cells (Tregs) and monocyte-derived supressor cells. Each of these cell types may be individual candidates for the prevention of brain injury following hypoxic and inflammatory events in the perinatal period. We will discuss specific properties of cell types in UCB, with respect to their therapeutic potential and the importance of optimal timing of administration. We propose that tailored cell therapy and targeted timing of administration will optimise results for future clinical trials in the neuroprotective treatment of perinatal brain injury.Pediatric Research accepted article preview online, 22 September 2017. doi:10.1038/pr.2017.236. PMID: 28937975 [PubMed - as supplied by publisher]Read more...